Abstract 4754
Background
Breast cancer is the second leading cause of cancer deaths among women. Most women with breast cancer undergo surgery and chemotherapy and/or radiotherapy. These treatments trigger various side effects, for example, shoulder immobility, numbness or tightness, and lymphedema of the arm. Exercise-induced adaptations and better muscular performance may attenuate mentioned symptoms and side effects. The aim of this research is to determine whether there is correlation between physical exercise and the relief of symptoms predominating during radiotherapy.
Methods
Study was designed as a longitudinal sudy. The participants were female patients hospitalized at Department for Oncology at Clinical Hospital Centre Osijek, with diagnosed breast cancer, who were treated with radiotherapy after mastectomy. Research was conducted with an anonymous questionnaire, designed for the purpose of this study.
Results
There were total of 36 respondents. There was correlation between feeling of worry about the course of the disease in the beginning and the end of treatment with opinion that targeted exercises will reduce the worry (Spearman’s rho 0,630, P < 0,001). Also, there was correlation between with opinion that targeted exercises will reduce the anger and assessment that exercises reduced that feeling (Spearman’s rho 0,625, P < 0,001). After the treatment, most of the respondents evaluated the benefit from exercise in reducing pain, anger, fear and worry with 4 on a scale from 1 do 5, and they evaluated the feeling that exercises helped them with grade 5 on a scale from 1 do 5. The majority of respondents expressed that they will continue to exercise at home.
Conclusions
In general, respondents had good attitudes toward physical activity. Most of them exercise few times weekly and they think that exercise is useful. They strongly agreed that they would recommend the exercise to other patients who are suffering from this disease, that they feel that exercises helped them and that their attitude about the importance of exercise changed in a positive direction.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2600 - Atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): a long-term overall survival (OS) and safety update from the Phase III IMvigor211 study
Presenter: Michiel Van der Heijden
Session: Poster Display session 3
Resources:
Abstract
3598 - Three-Year Follow-Up From the Phase 3 KEYNOTE-045 Trial: Pembrolizumab (Pembro) Versus Investigator’s Choice (Paclitaxel, Docetaxel, or Vinflunine) in Recurrent, Advanced Urothelial Cancer (UC)
Presenter: Andrea Necchi
Session: Poster Display session 3
Resources:
Abstract
2382 - First Report of Efficacy and Safety From a Phase 2 Trial of Tislelizumab, an Anti-PD-1 Antibody, for the Treatment of PD-L1+ Locally Advanced or Metastatic Urothelial Carcinoma (UC) in Asian Patients
Presenter: Dingwei Ye
Session: Poster Display session 3
Resources:
Abstract
2388 - Quality of Life of Metastatic Urothelial Cancer (mUC) Patients Treated with Enfortumab Vedotin (EV) Following Platinum-Containing Chemotherapy and a Checkpoint Inhibitor (CPI): Data from EV-201 Cohort 1
Presenter: Bradley McGregor
Session: Poster Display session 3
Resources:
Abstract
3748 - Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
1126 - Validation of the VIO prognostic index in patients with metastatic urothelial carcinoma treated with immune-checkpoint inhibitors
Presenter: Rafael Morales Barrera
Session: Poster Display session 3
Resources:
Abstract
3693 - Pathologic outcomes after neoadjuvant chemotherapy for high-risk muscle invasive bladder cancer
Presenter: Justin Matulay
Session: Poster Display session 3
Resources:
Abstract
4840 - Analysis of response to prior therapies and therapies after treatment with erdafitinib in fibroblast growth factor receptor (FGFR)-positive patients (pts) with metastatic urothelial carcinoma (mUC)
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract
1221 - Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)
Presenter: Jean Hoffman-censits
Session: Poster Display session 3
Resources:
Abstract
1715 - National Small Cell Bladder Cancer Audit: Results from 26 UK institutions
Presenter: Caroline Chau
Session: Poster Display session 3
Resources:
Abstract